2025 – Page 73 – Talk Bio

Fierce Health Payer Summit 2025: Shaping the Future of Healthcare Payers

4 months ago talkbio0Tagged Behavior, Fierce, Health, Health Payer Summit, Healthcare Industry, Healthcare Payers, payer-provider alignment, trends qualifier, Value-Based Care

Fierce Health Payer Summit, healthcare payers, value-based care, behavioral health, payer-provider alignment, healthcare industry trends.

Novo Nordisk and Variant Bio Collaborate on Metabolic Disease Research, Focusing on Diverse Populations

4 months ago talkbio0Tagged benefit-sharing program, Bio, Diversity, Genetic Research, geographic population, Metabolic Diseases, Nordisk, Variant, VB-Inference platform

Novo Nordisk, Variant Bio, Metabolic disease, Genetic research, Diverse populations, VB-Inference platform, Benefit-sharing program

FDA Updates Label for Agios’ PYRUKYND with New Liver Injury Warning

4 months ago talkbio0Tagged Agios, Cautionary Warning, Injury of liver, label update, Pyrukynd, Thalassemia, United States Food and Drug Administration

Agios Pharmaceuticals, PYRUKYND, mitapivat, liver injury warning, FDA label update, thalassemia treatment

Sanofi Partners with Alloy Therapeutics in $400M Deal to Advance Antisense Therapeutics

4 months ago talkbio0Tagged Alloys, Antisense, biobucks, Genetic Medicine, sanofi

Sanofi, Alloy Therapeutics, Antisense Therapeutics, Biobucks Deal, Genetic Medicine

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

4 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

4 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Aortic Valve Insufficiency, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.

Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials

4 months ago talkbio0Tagged Age related macular degeneration, AVD-104, Genus Aviceda, Geographic Atrophy, late-stage clinical trials, Macular edema due to diabetes mellitus, Series C

Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials